This provider's $12.1M in total Medicare payments ranks in the 98th percentile of Ophthalmology providers nationally.
Medicare payments to this provider grew 92% from 2014 to 2023.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $456.12 | $240.85 | 1.89x | $215.27 | $778.6K | 9.8K | 4.9K |
| 2015 | $615.31 | $303.83 | 2.03x | $311.48 | $996.5K | 10.9K | 5.2K |
| 2016 | $452.40 | $192.68 | 2.35x | $259.72 | $936.7K | 11.1K | 5.3K |
| 2017 | $280.05 | $137.69 | 2.03x | $142.36 | $1.0M | 11.9K | 5.4K |
| 2018 | $618.25 | $247.18 | 2.50x | $371.07 | $1.3M | 13.0K | 5.7K |
| 2019 | $414.53 | $180.73 | 2.29x | $233.80 | $1.2M | 12.6K | 5.5K |
| 2020 | $309.58 | $133.22 | 2.32x | $176.36 | $1.3M | 11.7K | 5.1K |
| 2021 | $723.80 | $191.87 | 3.77x | $531.93 | $1.6M | 13.5K | 5.2K |
| 2022 | $632.69 | $148.91 | 4.25x | $483.78 | $1.5M | 12.8K | 5.4K |
| 2023 | $1.1K | $279.51 | 4.03x | $847.54 | $1.5M | 12.4K | 4.9K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 5.5K | $4.0M | $728.12 | 2.15x |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 25.0K | $2.6M | $105.73 | 1.85x |
| 67028 | Injection of drug into eye | 13.4K | $1.4M | $104.34 | 5.06x |
| 92134 | Diagnostic imaging of retina | 29.1K | $1.1M | $37.37 | 4.37x |
| J2778 | Injection, ranibizumab, 0.1 mg | 2.3K | $635.3K | $277.55 | 1.80x |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | 4.1K | $411.4K | $100.95 | 1.96x |
| 92226 | Examination of eye by ophthalmoscope with retinal drawing | 15.0K | $333.7K | $22.22 | 2.14x |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | 2.3K | $315.8K | $136.28 | 1.84x |
| J9035 | Injection, bevacizumab, 10 mg | 3.6K | $206.3K | $57.75 | 1.68x |
| 92235 | Examination of retinal blood vessels by ophthalmoscope | 1.7K | $154.8K | $90.18 | 2.47x |
| 92202 | Extended examination of eye with drawing of optic nerve and surrounding area (macula) | 10.1K | $140.7K | $13.97 | 5.90x |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 785 | $123.7K | $157.64 | 2.06x |
| 67228 | Laser destruction of leaking retinal blood vessels, 1 or more sessions | 308 | $121.9K | $395.73 | 4.17x |
| 92250 | Photography of the retina | 1.4K | $81.9K | $60.20 | 2.04x |
| 67036 | Removal of eye fluid (vitreous) between the lens and retina | 97 | $77.8K | $802.29 | 3.30x |
| J7999 | Compounded drug, not otherwise classified | 817 | $59.4K | $72.73 | 6.01x |
| 92225 | Examination of eye by ophthalmoscope with retinal drawing | 1.6K | $37.9K | $24.19 | 2.19x |
| J3590 | Unclassified biologics | 14 | $37.6K | $2.7K | 3.07x |
| 67210 | Laser destruction of retinal growth, 1 or more sessions | 71 | $33.2K | $467.08 | 2.10x |
| 92201 | Extended examination of eye with drawing of retina | 1.4K | $30.5K | $21.08 | 4.23x |
This provider submits charges 2.69 times higher than what Medicare actually pays.
A markup ratio of 2.69x means for every $100 Medicare pays, this provider initially charges $269. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Ophthalmology providers in MD for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Michael Elman, M.D. | Baltimore, MD | $68.5M | ✓ Clear |
| David Warrow, M.D. | Hagerstown, MD | $65.5M | ✓ Clear |
| Raymond Sjaarda, M.D. | Baltimore, MD | $47.2M | ✓ Clear |
| Allen Hu, MD | Hagerstown, MD | $45.7M | ✓ Clear |
| James Rial, M.D. | Salisbury, MD | $45.2M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data